DexCom, IncNasdaq: DXCM
Health Care · Health Care Equipment
$72.50
+1.78%
Vol: 3.2M
Research Digest
Friday, June 19, 2026
Multiple analysts raise Dexcom price targets after landmark CONNECT trial proves CGM benefit in non-insulin Type 2 diabetes
Dexcom reported highly significant CONNECT trial results at the American Diabetes Association Scientific Sessions in early June 2026, demonstrating that the G7 continuous glucose monitor materially lowered A1C and improved glucose control in adults with Type 2 diabetes not using insulin versus traditional finger-stick testing — the largest addressable market expansion opportunity in Dexcom's history. Following the data, TD Cowen raised its price target to $95 from $75 (June 10), Mizuho raised to $85 from $75 (June 9), and Piper Sandler raised to $88 from $75 (June 15). On June 12, the FDA cleared Dexcom's over-the-counter CGM for children. The company also announced Dexcom Flex, a new CGM system for non-insulin Type 2 patients launching in Germany, and acquired Nutrisense for personalized nutrition coaching integration. The convergence of positive clinical evidence, multiple analyst upgrades, and new product launches represents the strongest positive catalyst cluster for DXCM in recent quarters.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16DexCom shares traded higher Monday June 15 after positive CONNECT trial data, with TD Cowen lifting its price target to $95 and reiterating Buy.Positive▶
DexCom stock moved higher on Monday June 15, 2026 as the market continued digesting positive results from its CONNECT randomized controlled trial, which the company has billed as the most significant study demonstrating CGM benefits for type 2 diabetes patients not using insulin. TD Cowen analyst Joshua Jennings raised his price target to $95 from $75 while maintaining a Buy rating, citing growing confidence in DexCom's growth trajectory and product pipeline. The CONNECT data, presented at the ADA Scientific Sessions on June 6, supports DexCom's push toward earlier-stage intervention and the broader non-insulin metabolic-health market via its Stelo product. Recent Q1 2026 revenue grew 15% year-over-year to $1.192 billion, and the company is expanding the G7 15 Day CGM and adding partnerships with Signos and Hims & Hers. The bear case is that DexCom still trades well off prior highs (around $75) amid competitive pressure in CGM and questions about how quickly the non-insulin market will monetize. Analyst price targets remain wide, ranging from $64 to $112.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21DexCom surged 6%+ after Investor Day setting 10% organic growth target through 2030 and $1B buybackPositive▶
DexCom held its Investor Day on May 14, 2026, announcing aggressive 2030 targets including 10%+ annual organic revenue growth, non-GAAP gross margin of 67-69% (vs prior 63-64%), and non-GAAP operating margin of 29-30% (vs prior 23-23.5%). The company also announced a new $1B share repurchase program through mid-2027 and plans to return at least 50% of annual free cash flow to buybacks. DexCom revealed governance enhancements following collaboration with activist Elliott Investment Management, adding two more independent directors. Product roadmap centers on G7 15 Day (rolling out 2026) and next-gen G8 (designed 50% smaller, more accurate, lower cost) targeted for late 2027/early 2028. Canaccord lifted target to $100. Risk: execution risk on long-term targets and competitive intensity in CGM market.
May 20Dexcom unveiled 2030 targets of 10%+ organic growth and $1B buyback at May 14 Investor Day, sending shares 6% higherPositive▶
At its May 14, 2026 Investor Day, Dexcom set ambitious 2030 targets: more than 10% organic revenue growth annually through 2030, gross margin of 67-69%, operating margin of 29-30%, and EBITDA margin of 36-37%. The company announced a fresh $1B share repurchase program through mid-2027, replacing a smaller prior plan. Q1 2026 delivered 12% organic sales growth to $1.19B with 22% adjusted operating margins. Activist Elliott Management is driving new independent directors and an Operations & Innovation Committee. Pipeline focus is G7 15-Day rolling out now and next-gen G8 in late 2027/early 2028 (50% smaller, lower cost). Shares jumped over 6% on the news.
May 19DexCom shares jumped 5.65% on May 18, 2026 as investors continued to digest the company's $1B buyback and 2030 double-digit growth targets unveiled at last week's Investor Day.Positive▶
DexCom stock climbed 5.65% on May 18, 2026 to extend the post-Investor Day rally, closing around $65.11. Management's May 14 presentation laid out long-term targets of more than 10% organic revenue growth annually through 2030, with non-GAAP gross margin of 67-69%, operating margin of 29-30%, and EBITDA margin of 36-37%. A fresh $1 billion share repurchase program through mid-2027 replaces the smaller prior plan, and management committed to returning at least 50% of annual free cash flow to buybacks. The company also detailed G7 15 Day adoption and a G8 sensor launch targeted for late 2027/early 2028 that will be 50% smaller and lower cost. Governance enhancements with Elliott Investment Management added two independent MedTech-experienced directors. The risk is execution on margin expansion against ongoing competition from Abbott's Libre franchise.
May 18DexCom Investor Day (May 14) unveils 10%+ annual organic growth target through 2030 and $1B share buyback; shares jumped 6%Positive▶
DexCom hosted Investor Day on May 14, 2026, setting long-term targets of >10% organic revenue growth annually through 2030, gross margin of 67-69%, operating margin of 29-30%, and EBITDA margin of 36-37%. The Board authorized a new $1.0 billion share repurchase program through June 30, 2027, replacing a prior plan with $250M remaining. Governance was enhanced by adding two independent directors with MedTech/operations experience and reconstituting an Operations and Innovation Committee, following engagement with Elliott Investment Management. Q1 delivered 12% organic growth to $1.19B with 22% adjusted operating margins. Shares rose 6.02% on May 15. Canaccord raised PT to $100; Benchmark initiated Buy with $77 target.
May 15DexCom hosted May 14 Investor Day and announced governance changes including Elliott Investment Management board settlement adding two independent directors.Positive▶
On May 14, 2026, DexCom held its Investor Day from 1:15-3:30 PM PDT outlining strategic vision and long-term financial outlook. Ahead of the event, DexCom announced governance changes - activist Elliott Investment Management took a stake and reached a settlement to add two independent directors to the board, with the new directors then collaborating to appoint two more directors with medical technology and operations expertise. Q1 2026 results released May 1 showed revenue of $1.19B (+15% YoY) and non-GAAP EPS $0.56 (19% above consensus). The company reaffirmed 2026 revenue guidance of $5.16B-$5.25B with raised margin outlook. DexCom is ceasing G6 CGM production next year to shift fully to G7. Multiple analysts (Jefferies, Goldman, Piper Sandler, Stifel, Truist, RBC, William Blair, BTIG) maintained Buy ratings. Stock at $61.14. Risks include U.S. growth moderation and reimbursement dynamics.
May 14DexCom hosting Investor Day May 14 to outline long-term financial outlook after strong Q1 with 15% revenue growth and 89% net income surgeMixed▶
DexCom hosting Investor Day Thursday May 14 from 1:15pm PT to outline long-term financial outlook and innovation roadmap. Q1 2026 revenue of $1.19B (+15%), EPS $0.52 vs $0.27 prior year, net income up 89% to $199.5M. Reaffirmed FY26 revenue guidance of $5.16-5.25B with raised margin outlook. Multiple analysts (Goldman, Piper, Raymond James, Stifel, Truist, RBC, William Blair, BTIG, Canaccord, Barclays) issued mixed PT changes post-print. Stock $58.63 May 13, slipping into Investor Day. Risk: G6 to G7 transition and competitive CGM landscape (Abbott Libre).
May 13Dexcom hosts Investor Day tomorrow (May 14) to outline long-term strategy after Q1 2026 revenue of $1.19B (+15% YoY) and reaffirmed FY guidance.Positive▶
DexCom hosts its Investor Day on Thursday, May 14, 2026 to outline long-term financial outlook and innovation priorities. Q1 2026 results showed revenue of $1.19B (+15% YoY) and net income of $199.5M with margin improvement. The company reaffirmed FY2026 revenue guidance of $5.16B-$5.25B. Analyst views remain mixed: Citi raised PT to $84 from $77 (Buy) while Barclays cut PT to $67 from $72 (Underweight). The consensus is Moderate Buy with average PT of $83.50. CGM coverage expansion has been a recent positive catalyst.
May 12DexCom hosts May 14 Investor Day to outline long-term outlook after Q1 2026 revenue of $1.19B (+15% YoY); Barclays cut PT to $67 from $72.Mixed▶
DexCom delivered Q1 2026 revenue of $1.19B, up 15% YoY, and reaffirmed full-year guidance of $5.16B-$5.25B, supported by international sales and margin improvements. The company is scheduled to host an Investor Day on May 14, 2026, to outline long-term financial outlook and innovation priorities. Analyst sentiment was mixed post-earnings, with Barclays lowering its price target to $67 from $72 while maintaining an Underweight rating. Shares traded in a narrow $61.00-$61.35 range on May 8. Investors look to the Investor Day for catalyst clarity.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| DXCMDEXCOM | $72.50 | +1.78% | +2.1% | 23.1x | 1.45 | $27.5B |
| ABTABBOTT | $88.64 | +0.16% | +5.4% | 15.8x | 0.61 | $166.2B |
| ISRGINTUITIVE | $406.90 | +1.17% | +6.0% | 36.1x | 1.46 | $150.9B |
| SYKSTRYKER | $309.23 | +2.68% | +4.1% | 19.5x | 0.78 | $125.2B |
| MDTMEDTRONIC | $79.43 | +1.64% | +3.8% | 13.0x | 0.58 | $106.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.